DNA-PK-IN-3 is a highly potent inhibitor of DNA-PK. This compound exerts a synergistic effect when combined with radiotherapy and chemotherapy, resulting in enhanced therapeutic outcomes and significant inhibition of tumor growth. Furthermore, DNA-PK-IN-3 demonstrates remarkable efficacy in reducing damage to normal cells, effectively minimizing adverse side effects. Due to these compelling properties, DNA-PK-IN-3 holds great potential for cancer research applications[1].
Drak2-in-1, a potent, selective and ATP-competitive DRAK2 inhibitor, has an IC50 and KIvalue of 3 nM and 0.26 nM, respectively.Drak2-in-1 also had an effect on DRAK1 (IC50=51 nM).